Nyxoah S.A. (5YI)
XMUN 
Summary
5YI Chart
Nyxoah Gains Favorable CMS Reimbursement Ruling for Genio System
Nyxoah secures a finalized CMS rule that sharply lifts 2026 reimbursement for Genio implants, opening fresh momentum for its OSA therapy.
Nyxoah SA (NYXH) Q3 2025 Earnings Call Transcript
Nyxoah SA ( NYXH ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Pearson Dennis Olivier Taelman - CEO & Executive Director John Landry - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald & Co., Research Division Adam Maeder - Piper Sandler & Co., Research Division Suraj Kalia - Oppenheimer & Co. Inc., Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division David Rescott - Robert W. Baird & Co. Incorporated, Research Division Paige Chamberlain - Wolfe Research, LLC Presentation Operator Good day, and thank you for standing by.
Nyxoah SA (NYXH) Reports Q3 Loss, Beats Revenue Estimates
Nyxoah SA (NYXH) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to a loss of $0.55 per share a year ago.
Nyxoah S.A. (5YI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Nyxoah S.A. ever had a stock split?
Nyxoah S.A. Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Olivier Taelman CEO | XMUN Exchange | BE0974358906 ISIN |
| BE Country | 183 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Nyxoah S.A. is a pioneering medical technology company, established in 2009, with a strategic focus on inventing, developing, and commercializing innovative solutions targeted at treating sleep disordered breathing conditions, specifically obstructive sleep apnea (OSA). With its headquarters located in Mont-Saint-Guibert, Belgium, Nyxoah has positioned itself as a key player in the sleep health industry, aiming to improve patient outcomes and quality of life through its cutting-edge therapeutic technologies. Through years of research and development, Nyxoah strives to address the critical needs of OSA patients, offering them an effective alternative to conventional treatment methods.
Products and Services
- Genio System
The Genio system stands as Nyxoah's flagship solution, a testament to the company's innovative approach in treating moderate to severe obstructive sleep apnea. This CE-Marked product differentiates itself through a patient-centric design, which delicately balances efficacy with user comfort. The Genio system utilizes a groundbreaking hypoglossal neurostimulation therapy, ingeniously targeting the muscle control of the tongue to keep the airway open during sleep. This method not only represents a significant leap forward in OSA treatment but also ensures that patients experience minimal discomfort and disruption during use. Nyxoah's commitment to enhancing patient care quality through the Genio system underlines their dedication to advancing sleep medicine.
Contact Information
